The claims cover the use of luteinizing hormone (LH) or human chorionic gonadotrophin (hCG) and erythropotein (EPO) for producing neural stem cells (in vitro & in vivo), which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The covered in vivo uses include administration of these compounds to subjects having neurodegenerative conditions, diseases and CNS injuries. This is the first U.S. patent to issue in this patent family and it protects the use of the NTx(R)-265 regimen in the acute neurologic injury indications of Stroke, and Traumatic Brain Injury, amongst other indications.
Dr. Allen Davidoff, SCT's Chief Scientific Officer, commented as follows:
"We at SCT are very excited to see this patent issue as it represents an important intellectual property milestone for the NTx(R)-265 program. This patent offers protection and support for our NTx(R)-265 technology, a keystone patent, while expanding and increasing value to SCT's overall intellectual property portfolio."